Actavis Inc (ACT) 201.86 $ACT
Stocks Add To Gains; Intuitive Surgical Slumps On Warning
at Investor's Business Daily - Wed Apr 09, 11:04AM CDT
Stocks extended gains Wednesday after Tuesday's lower-volume rally. About two hours into the session, the Nasdaq led the way, up 0.5%. The Dow Jones industrial average and S&P 500 added 0.2% each. NYSE and Nasdaq volume was tracking considerably...
Mallinckrodt plc (MNK) in Focus: Stock Moves 5.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:37AM CDT
Mallinckrodt plc as the company saw its shares rise more than 5% on the day.
Alexion, Biogen Among Leading Big-Cap Biotechs
at Investor's Business Daily - Wed Apr 09, 7:02AM CDT
Growth stocks are taking a hit now that the market is in a correction. Biotechs saw a recent sell-off over concerns that the sector was overheating, but biotechs and medical stocks are among leading big-cap stocks. IBD's Big Cap Screen of the Day...
Upcoming Results and Conference Call Schedules, New Office Facility, and Stock Price Movements-Analyst Notes on Biogen, Actavis, Bristol-Myers, AbbVie, and Baxter
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Actavis Plc (NYSE: ACT), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pacira and Patheon Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:10PM CDT
Pacira has signed a strategic co-production partnership deal with Patheon.
Additional Data on Pacira's Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:20PM CDT
Pacira announced additional phase III data on its lead product, Exparel.
Stocks Higher In Late Afternoon; First Solar Jumps
at Investor's Business Daily - Tue Apr 08, 2:02PM CDT
The Nasdaq outperformed in late afternoon trading Tuesday, but gains in the other major indexes were fading. The Nasdaq rose 0.5%, the S&P 500 gained 0.2% and the Dow Jones industrial average slipped 0.1%. NYSE volume was tracking slightly higher...
Stocks Rally, Stall, Turn Mixed; Consol Energy, U.S. Steel Jump
at Investor's Business Daily - Tue Apr 08, 9:29AM CDT
Early gains quickly flickered into a mixed performance Tuesday, with China-based stocks grabbing a large share of early gains. The Nasdaq bobbed to a 0.2% gain. The S&P 500 eased 0.1%. The Dow Jones industrial average dipped 0.2%. Volume was mixed,...
Caesarstone, Other Leaders Show Supporting Action
at Investor's Business Daily - Fri Apr 04, 4:49PM CDT
Even as market volatility increased in recent weeks, some leaders have managed to find support at their 10-week lines or are close to that key moving average. Caesarstone (CSTE) found support at its 10-week moving average two weeks ago. It tested the...
Mylan Rejected In Bid To Acquire Sweden's Meda
at Investor's Business Daily - Fri Apr 04, 11:27AM CDT
Generic-drug giant Mylan (MYL) on Friday lost out in a takeover bid for Swedish counterpart Meda, but its stock was still up more than 4% in midday trading on the stock market. Late Thursday, Britain's Financial Times reported that Mylan and Meda...
Actavis Up Slightly on Silom Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 2:56PM CDT
Actavis acquired Thailand-based generic company, Silom Medical Company.
Actavis inaugurates new regional headquarters in Singapore for APACA
M2 - Thu Apr 03, 5:36AM CDT
Pharmaceutical company, Actavis (NYSE:ACT) reported on Wednesday the official opening of its new regional headquarters in Singapore for its Asia Pacific and Africa (APACA) region under its global expansion strategy.
Actavis Launches Asia Pacific Regional Headquarters in Singapore
PR Newswire - Wed Apr 02, 7:00PM CDT
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa (APACA) region.
Four Top World Stocks Offer Follow-On Buy Points
at Investor's Business Daily - Wed Apr 02, 5:11PM CDT
The market's resumed uptrend doesn't come with the clean slate that a sharp correction followed by a follow-through day would offer. A striking eight distribution days levied against the Nasdaq hold out a bright red flag for investors. But the shift...
Particle Sciences partners with Actavis to develop a complex generic product
M2 - Wed Apr 02, 4:27AM CDT
Drug delivery company Particle Sciences disclosed on Tuesday the launch of an exclusive agreement to develop an unnamed complex generic product.
Actavis
at Investor's Business Daily - Tue Apr 01, 5:41PM CDT
Actavis (ACT) said it has bought privately-held Silom Medical for about $100 mil cash. The generic and branded drugmaker expects the acquisition to be immediately accretive to earnings. Silom focuses on developing and selling generics in Thailand....
Pacira Up as Exparel Site Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:00PM CDT
Pacira Pharma's shares gained 10.7% after the FDA approved of an additional manufacturing suite (Suite C) for Exparel.
Positive Data on Forest Labs/Gedeon's Cariprazine - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:40PM CDT
Forest Labs and partner Gedeon Richter's antipsychotic candidate, cariprazine, met the primary endpoint in a phase IIb study.
Particle Sciences and Actavis Enter into Joint Development Agreement
PR Newswire - Tue Apr 01, 10:00AM CDT
Particle Sciences, a drug delivery Contract Development and Manufacturing Organization (CDMO), today announced that they have entered into an exclusive agreement with Actavis plc (NYSE: ACT), a leading specialty pharmaceutical company, to develop an unnamed complex generic product. Under the agreement, Particle Sciences is responsible for design, formulation and cGMP supplies. Actavis will have responsibility for clinical testing, regulatory filings and marketing.
Actavis plans to spend $100M on generic drugmaker
By The Associated Press - AP - Tue Apr 01, 9:33AM CDT
Drugmaker Actavis Plc plans to expand its reach into Southeast Asia by spending about $100 million to buy Silom Medical Co., a generic pharmaceutical company focused on Thailand.
Stocks Add To Gains; Intuitive Surgical Slumps On Warning
at Investor's Business Daily - Wed Apr 09, 11:04AM CDT
Stocks extended gains Wednesday after Tuesday's lower-volume rally. About two hours into the session, the Nasdaq led the way, up 0.5%. The Dow Jones industrial average and S&P 500 added 0.2% each. NYSE and Nasdaq volume was tracking considerably...
Mallinckrodt plc (MNK) in Focus: Stock Moves 5.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:37AM CDT
Mallinckrodt plc as the company saw its shares rise more than 5% on the day.
Alexion, Biogen Among Leading Big-Cap Biotechs
at Investor's Business Daily - Wed Apr 09, 7:02AM CDT
Growth stocks are taking a hit now that the market is in a correction. Biotechs saw a recent sell-off over concerns that the sector was overheating, but biotechs and medical stocks are among leading big-cap stocks. IBD's Big Cap Screen of the Day...
Upcoming Results and Conference Call Schedules, New Office Facility, and Stock Price Movements-Analyst Notes on Biogen, Actavis, Bristol-Myers, AbbVie, and Baxter
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Actavis Plc (NYSE: ACT), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pacira and Patheon Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:10PM CDT
Pacira has signed a strategic co-production partnership deal with Patheon.
Additional Data on Pacira's Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:20PM CDT
Pacira announced additional phase III data on its lead product, Exparel.
Stocks Higher In Late Afternoon; First Solar Jumps
at Investor's Business Daily - Tue Apr 08, 2:02PM CDT
The Nasdaq outperformed in late afternoon trading Tuesday, but gains in the other major indexes were fading. The Nasdaq rose 0.5%, the S&P 500 gained 0.2% and the Dow Jones industrial average slipped 0.1%. NYSE volume was tracking slightly higher...
Stocks Rally, Stall, Turn Mixed; Consol Energy, U.S. Steel Jump
at Investor's Business Daily - Tue Apr 08, 9:29AM CDT
Early gains quickly flickered into a mixed performance Tuesday, with China-based stocks grabbing a large share of early gains. The Nasdaq bobbed to a 0.2% gain. The S&P 500 eased 0.1%. The Dow Jones industrial average dipped 0.2%. Volume was mixed,...
Caesarstone, Other Leaders Show Supporting Action
at Investor's Business Daily - Fri Apr 04, 4:49PM CDT
Even as market volatility increased in recent weeks, some leaders have managed to find support at their 10-week lines or are close to that key moving average. Caesarstone (CSTE) found support at its 10-week moving average two weeks ago. It tested the...
Mylan Rejected In Bid To Acquire Sweden's Meda
at Investor's Business Daily - Fri Apr 04, 11:27AM CDT
Generic-drug giant Mylan (MYL) on Friday lost out in a takeover bid for Swedish counterpart Meda, but its stock was still up more than 4% in midday trading on the stock market. Late Thursday, Britain's Financial Times reported that Mylan and Meda...
Actavis Up Slightly on Silom Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 2:56PM CDT
Actavis acquired Thailand-based generic company, Silom Medical Company.
Actavis inaugurates new regional headquarters in Singapore for APACA
M2 - Thu Apr 03, 5:36AM CDT
Pharmaceutical company, Actavis (NYSE:ACT) reported on Wednesday the official opening of its new regional headquarters in Singapore for its Asia Pacific and Africa (APACA) region under its global expansion strategy.
Actavis Launches Asia Pacific Regional Headquarters in Singapore
PR Newswire - Wed Apr 02, 7:00PM CDT
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa (APACA) region.
Four Top World Stocks Offer Follow-On Buy Points
at Investor's Business Daily - Wed Apr 02, 5:11PM CDT
The market's resumed uptrend doesn't come with the clean slate that a sharp correction followed by a follow-through day would offer. A striking eight distribution days levied against the Nasdaq hold out a bright red flag for investors. But the shift...
Particle Sciences partners with Actavis to develop a complex generic product
M2 - Wed Apr 02, 4:27AM CDT
Drug delivery company Particle Sciences disclosed on Tuesday the launch of an exclusive agreement to develop an unnamed complex generic product.
Actavis
at Investor's Business Daily - Tue Apr 01, 5:41PM CDT
Actavis (ACT) said it has bought privately-held Silom Medical for about $100 mil cash. The generic and branded drugmaker expects the acquisition to be immediately accretive to earnings. Silom focuses on developing and selling generics in Thailand....
Pacira Up as Exparel Site Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:00PM CDT
Pacira Pharma's shares gained 10.7% after the FDA approved of an additional manufacturing suite (Suite C) for Exparel.
Positive Data on Forest Labs/Gedeon's Cariprazine - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:40PM CDT
Forest Labs and partner Gedeon Richter's antipsychotic candidate, cariprazine, met the primary endpoint in a phase IIb study.
Particle Sciences and Actavis Enter into Joint Development Agreement
PR Newswire - Tue Apr 01, 10:00AM CDT
Particle Sciences, a drug delivery Contract Development and Manufacturing Organization (CDMO), today announced that they have entered into an exclusive agreement with Actavis plc (NYSE: ACT), a leading specialty pharmaceutical company, to develop an unnamed complex generic product. Under the agreement, Particle Sciences is responsible for design, formulation and cGMP supplies. Actavis will have responsibility for clinical testing, regulatory filings and marketing.
Actavis plans to spend $100M on generic drugmaker
By The Associated Press - AP - Tue Apr 01, 9:33AM CDT
Drugmaker Actavis Plc plans to expand its reach into Southeast Asia by spending about $100 million to buy Silom Medical Co., a generic pharmaceutical company focused on Thailand.
